About
Bacterial resistance to antibiotics has become a major public health issue. A recent report, delivered to the Minister of Health in September 2015, pointed out 158,000 cases of infections by antibiotic-resistant bacteria annually in France, 16,000 invasive infections (meningitis, bacteremia / septicemia) and nearly 12,000 deaths per year directly associated with these infections. These estimates are from the Burden BMR study conducted by the National Institute of Public Health (Santé Publique France).
The PHIBRA (Public Health Impact of the Bacterial Resistance to Antibiotics) program focuses on the consequences, including economic consequences, of bacterial resistance to antibiotics in France. A component of this program is based on the medico-administrative databases (SNDS) to investigate the epidemiological cost of resistance in terms of mortality, duration of hospitalization, post-hospital care, etc. and additional economic cost linked to the presence of antibiotic-resistant bacteria during the infection.
Keywords: Bacterial resistance to antibiotics, Invasive/acute infection, SNDS
Scientific Partners
- Philippe Tuppin, Caisse Nationale de l’Assurance Maladie (Cnam)
Former
- Grégoire de Lagasnerie, Caisse Nationale de l’Assurance Maladie (Cnam)
- Kristel Cosker, Assitance publique-Hôpitaux de Paris (AP-HP)
- Medhi Touat, PhD thesis defended on January 22, 2020
Partners
- DATAD of the Direction de la Stratégie, des Études et des Statistiques (DSES), Caisse Nationale de l’Assurance Maladie (Cnam)
Fundings
